http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109985046-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-568 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-568 |
| filingDate | 2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109985046-B |
| titleOfInvention | 5 alpha-androst-3 beta, 5,6 beta-triol for the treatment of inflammation mediated optic neuropathy |
| abstract | The invention discloses an application of 5 alpha-androstane-3 beta, 5,6 beta-triol, a deuteron thereof or a pharmaceutically acceptable salt thereof in preparing a medicament for treating inflammation-mediated optic neuropathy of a patient. The invention proves that the 5 alpha-androstane-3 beta, 5,6 beta-triol can obviously antagonize the activation of microglia and macrophage, inhibit inflammatory reaction so as to reduce the loss of rat optic ganglion cells caused by high intraocular pressure and reduce the loss of retina ganglion cell axons, thereby being capable of being used for treating inflammation-mediated optic neuropathy. |
| priorityDate | 2017-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 228.